SARS-CoV-2 mRNA Vaccine ARCT-021 + Tozinameran
Phase 2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hematopoietic and Lymphatic System Neoplasm
Conditions
Hematopoietic and Lymphatic System Neoplasm
Trial Timeline
Sep 1, 2026 → Jan 1, 2029
NCT ID
NCT07390968About SARS-CoV-2 mRNA Vaccine ARCT-021 + Tozinameran
SARS-CoV-2 mRNA Vaccine ARCT-021 + Tozinameran is a phase 2 stage product being developed by Arcturus Therapeutics for Hematopoietic and Lymphatic System Neoplasm. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07390968. Target conditions include Hematopoietic and Lymphatic System Neoplasm.
What happened to similar drugs?
1 of 3 similar drugs in Hematopoietic and Lymphatic System Neoplasm were approved
Approved (1) Terminated (1) Active (1)
Hype Score Breakdown
Clinical
12
Activity
15
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07390968 | Phase 2 | Recruiting |
Competing Products
20 competing products in Hematopoietic and Lymphatic System Neoplasm